Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
LetterLetter to the Editor

BINDING OF DRUGS TO HEPATIC MICROSOMES: COMMENT AND ASSESSMENT OF CURRENT PREDICTION METHODOLOGY WITH RECOMMENDATION FOR IMPROVEMENT

David Hallifax and J. Brian Houston
Drug Metabolism and Disposition April 2006, 34 (4) 724-726; DOI: https://doi.org/10.1124/dmd.105.007658
David Hallifax
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Brian Houston
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

This article has a correction. Please see:

  • CORRECTION TO “BINDING OF DRUGS TO HEPATIC MICROSOMES: COMMENT AND ASSESSMENT OF CURRENT PREDICTION METHODOLOGY WITH RECOMMENDATION FOR IMPROVEMENT” - June 01, 2006

In recent years the phenomenon of hepatic microsomal nonspecific binding of drugs has received considerable attention in this journal, as well as in others. There is general agreement on the need to correct kinetic constants (namely, Km and Ki values) for the fraction of drug concentration unbound (fuinc) to ensure optimal prediction of clearance and inhibition potential in vivo from in vitro hepatic microsomal studies (Tucker et al., 2001; Bjornsson et al., 2003). The ability to predict in silico the extent of microsomal binding from a drug's physicochemical properties, as proposed by Austin et al. (2002), is an attractive option that has engendered much interest. Recently, the same authors have extended earlier principles from microsomes to intact hepatocytes (Austin et al., 2005) and have shown application to various sets of hepatocyte and microsomal clearance data (Riley et al., 2005).

Having demonstrated a relationship between the charge-dependent lipophilicity parameter “logP/D” and binding affinity to microsomes for a range of drugs, Austin et al. (2002) proposed that the fuinc could be predicted using a simple linear relationship. This method was based on a theoretical combination of the above relationship and the ability to project fuinc from one concentration of microsomes to another. As no evaluation of prediction outcome was provided, we have assessed the prediction of fuinc using the Austin equation. A dataset including the 56 drugs used in the original study together with an additional 36 drugs both from other published studies (Obach, 1999; Naritomi et al., 2001; Soars et al., 2002) and from our own unpublished work was used.

First, we examined logP values from several sources (including experimental and in silico) for as many drugs for which data were available but found no major influence of source; mean logP values were therefore used, and these were converted to logD values where appropriate. Binding affinity (Ka) values were calculated from experimental microsomal fuinc values, and the latter were converted to values corresponding to 1 mg microsomal protein per ml, as required; when several experimental values were obtained for the same drug, a mean value was used. In demonstrating the relationship between binding affinity and logP/D, Austin et al. (2002) deliberately omitted drugs weakly bound (fu >0.9)—effectively excluding acidic drugs—and justified this based on the relative difficulty in determining minor binding and the fact that this degree of binding was not important. Figure 1A shows the relationship between binding affinity and logP/D for all of the basic and neutral drugs in the extended database (n = 64). The fitted linear relationship is similar to that obtained by Austin et al. (2002), and the correlation (r2 = 0.68) is comparable despite the increase in the number of drugs used. The linear equation parameters obtained using this extended database analysis were substituted into the Austin equation, and the resultant predicted fuinc values for all drugs were compared with observed values of fuinc. This prediction calculation typically resulted in underprediction of fuinc across the range of binding (average fold error = –1.5); 65% of all fuinc predictions were less than the observed fuinc values. In terms of precision, 28% of the predictions were greater than 2-fold different from observed.

The charge-dependent parameter, logP/D, suggested by Austin et al. (2002) does show the most consistent trend between both drug type and individual drugs, including acidic drugs, when compared with logP or logD. It does not seem justified to exclude acidic drugs in quantifying this relationship because they provide limiting values within this inclusive property. Figure 1B, which includes all the drugs, shows that the relationship between binding affinity and logP/D is not linear. Any mechanistic model for microsomal binding would involve a polar interaction as well as a lipophilic/hydrophobic interaction, and so it is not surprising that the overall interaction is more complex than a simple linear relationship. As an alternative empirical approach, we fitted a quadratic relationship to all the data in the extended database and modified the fuinc prediction to that given in the equation below. Math

Despite a similar degree of correlation for the nonlinear affinity relationship (R′2 = 0.75) compared with the linear relationship (R′2 = 0.68), the resultant prediction calculation (average fold error = 1.1) successfully eliminated the negative bias found when applying the linear equation to prediction of fuinc (Fig. 1B). This represents a useful improvement on the Austin prediction method, although the precision of prediction remains approximately the same, with 25% of the predictions outside 2-fold accuracy.

Drug amphiphilicity may be an important prerequisite for binding to microsomes, with strong binding being associated with a charged amine moiety in combination with a multiple aromatic/cyclic hydrophobic moiety. However, few drug molecules are this simple, and greater precision of prediction might only be achieved by mechanistic modeling of additional binding traits such as molecule shape, type and location of additional polar/functional groups, etc. Despite these caveats, there is a strong general trend in binding affinity with lipophilicity, which can be represented in a relatively simple nonlinear manner.

Consideration of neutral and basic drugs separately further illustrates the inadequacy of the linear relationship assumed in the Austin equation. In the case of neutrals, which are mostly moderately bound, inaccuracy in the fuinc values predicted by the linear model can be explained simply by a constant overestimation of affinity. Figure 1C shows the predicted fuinc (based on the linear equation) with a fitted bias for affinity. For bases, however, the fuinc values predicted by the linear model seem to diverge from observed fuinc in a disproportionate manner with increasing fuinc (Fig. 1D). In other words, as binding affinity of bases decreases, increasingly biased estimates of affinity are provided; in both cases, this misrepresentation is resolved using the quadratic model [Fig. 1, E (neutrals) and F (bases)].

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Prediction of microsomal binding from logP/D relationships. Relationship between logP/D and binding affinity for neutral and basic drugs (n = 64) with linear fit (A), and for acids, neutrals, and bases (n = 92) with quadratic fit (B). Relationship between fuinc observed and fuinc was predicted using the linear model for neutrals (C) and bases (D), and using a quadratic relationship (E and F, respectively). Dashed lines denote the line of identity; solid lines indicate the resultant relationship between observed and predicted from either arbitrarily using a power trend line (D–F) or by determination of fu by applying a fitted bias on the affinity constant (C).

Austin and coworkers have also advocated a linear relationship for the intracellular binding of drugs within hepatocytes (Austin et al., 2005) and, hence, an fuinc term for this in vitro system. For hepatocytes, although it seems that a major role for lipophilicity is reflected in the trend of logP/D with binding affinity, it would seem that inaccuracies similar to those we describe for microsomes may result. Furthermore, intracellular binding is not the sole reason for cell-to-medium concentration ratios differing from unity. The latter parameter is also affected by membrane transporter activity and is often concentration-dependent (Jones et al., 2004). Thus, for hepatocyte experiments, there is little support for the linear fuinc assumption, and so its validity is questioned.

In summary, the relationship between fu in microsomes and the lipophilicity parameter logP/D can be best described by a nonlinear empirical equation which allows unbiased predictions unlike those based on an assumed linear relationship.

Footnotes

  • Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

  • doi:10.1124/dmd.105.007658.

    • Received September 29, 2005.
    • Accepted January 11, 2006.
  • The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    Austin RP, Barton P, Cockroft SL, Wenlock MC, and Riley RJ (2002) The influence of non-specific microsomal binding on apparent intrinsic clearance and its prediction from physicochemical properties. Drug Metab Dispos 30: 1497–1503.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Austin RP, Barton P, Mohmed S, and Riley RJ (2005) The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab Dispos 33: 419–425.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31: 815–832.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Jones HM, Hallifax D, and Houston JB (2004) Quantitative prediction of the in vivo inhibition of diazepam metabolism by omeprazole using rat liver microsomes and hepatocytes. Drug Metab Dispos 32: 572–580.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, and Sugiyama Y (2001) Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29: 1316–1324.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal clearance data: an examination of in vitro half-life approach and non-specific binding to microsomes. Drug Metab Dispos 27: 1350–1359.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Riley RJ, McGinnity DF, and Austin RP (2005) A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33: 1304–1311.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Soars MG, Burchell B, and Riley RJ (2002) In vitro analysis of human drug glucuronidation and prediction of in vitro metabolic clearance. J Pharmacol Exp Ther 301: 382–390.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Tucker GT, Houston JB, and Huang S-M (2001) Optimising drug development: strategies to assess drug metabolism/transporter interaction potential—toward a consensus. Clin Pharmacol Ther 70: 103–114.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 34 (4)
Drug Metabolism and Disposition
Vol. 34, Issue 4
1 Apr 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
BINDING OF DRUGS TO HEPATIC MICROSOMES: COMMENT AND ASSESSMENT OF CURRENT PREDICTION METHODOLOGY WITH RECOMMENDATION FOR IMPROVEMENT
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
LetterLetter to the Editor

BINDING OF DRUGS TO HEPATIC MICROSOMES: COMMENT AND ASSESSMENT OF CURRENT PREDICTION METHODOLOGY WITH RECOMMENDATION FOR IMPROVEMENT

David Hallifax and J. Brian Houston
Drug Metabolism and Disposition April 1, 2006, 34 (4) 724-726; DOI: https://doi.org/10.1124/dmd.105.007658

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
LetterLetter to the Editor

BINDING OF DRUGS TO HEPATIC MICROSOMES: COMMENT AND ASSESSMENT OF CURRENT PREDICTION METHODOLOGY WITH RECOMMENDATION FOR IMPROVEMENT

David Hallifax and J. Brian Houston
Drug Metabolism and Disposition April 1, 2006, 34 (4) 724-726; DOI: https://doi.org/10.1124/dmd.105.007658
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Unbound Maximum Hepatic Inlet Concentration
  • Misidentification of Bupropion Glucuronide Metabolites
  • Response to Letter to the Editor
Show more Letters to the Editor

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics